Lactivicin compounds, their preparation and use as antibacterial agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The emergence of antibiotic-resistant bacteria, particularly Gram-negative pathogens, poses a significant public health concern, as existing β-lactam antibiotics are rendered ineffective by β-lactamases, necessitating the development of new antibacterial agents with enhanced activity against these resistant strains.
Innovation Solution
Development of novel lactivicin compounds with a dicyclic dipeptide structure, incorporating a bicyclic catechol or hydroxypyridone moiety to enhance intracellular uptake via bacterial iron uptake processes, and potentially combined with β-lactamase inhibitors for synergistic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If β-lactam antibiotics are used to treat Gram-negative bacterial infections, then treatment effectiveness is improved, but bacterial resistance develops due to β-lactamase production
Solution Approach 1:
The patent changes the chemical structure parameter from β-lactam to lactivicin dicyclic dipeptide structure, which fundamentally alters how the antibiotic interacts with bacterial targets. This structural parameter change allows the compound to bind to PBPs while resisting β-lactamase hydrolysis, thereby maintaining treatment effectiveness against resistant bacteria
Solution Approach 2:
The patent creates a composite molecular structure combining the dicyclic dipeptide core of lactivicin with various acylamino side chains at the C-4 position. This composite approach allows optimization of both antibacterial activity and resistance to β-lactamases by selecting appropriate side chain configurations
2Reliability
If new antibiotic classes are developed to overcome resistance, then activity against resistant bacteria is improved, but development complexity and time increase
Solution Approach 1:
The patent segments the lactivicin molecule into distinct functional regions: the core dicyclic dipeptide structure that provides β-lactamase resistance and PBP binding capability, and the variable acylamino side chain at C-4 that can be optimized for specific antibacterial activity. This segmentation allows systematic development of new compounds by modifying side chains while retaining the resistant core structure
3Reliability
If lactivicin derivatives with various acylamino moieties are synthesized, then antibacterial activity is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent applies local quality by modifying only the C-4 acylamino side chain region of the lactivicin molecule while keeping the core dicyclic dipeptide structure unchanged. This allows optimization of antibacterial activity at the local side chain level without affecting the overall molecular scaffold, simplifying manufacturing by reusing the same core synthesis pathway
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lactivicin compounds demonstrate potent antibacterial activity against resistant Gram-negative bacteria, offering a new class of antibiotics that are less susceptible to β-lactamases and provide effective treatment options for infections.
Implementation Method 1
incorporating a bicyclic catechol or hydroxypyridone moiety to enhance intracellular uptake via bacterial iron uptake processes
Data Source
AI summary
Lactivicin compounds of formula (I) and pharmaceutically acceptable salts of the compounds of formula (I) are provided, wherein the compounds comprise antibiotics suitable for use either alone or in combination with P-lactamase inhibitors and/or other antibiotics (including P-lactam and non-P-lactam antibiotics) in the treatment or prevention of bacterial infections.